Clopidogrel and ticagrelor are two antiplatelet medications commonly prescribed for patients at risk of thrombotic cardiovascular events, such as heart attacks and strokes. Both medications play a critical role in managing cardiovascular diseases by preventing the aggregation of platelets, which can lead to the formation of blood clots. While they share a common goal of reducing the risk of serious cardiovascular events, they differ in their mechanisms of action, dosing, and potential side effects. Understanding the nuances between clopidogrel and ticagrelor is essential for healthcare providers and patients alike. As cardiovascular diseases remain a leading cause of morbidity and mortality worldwide, the choice of antiplatelet therapy can significantly impact patient…